Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients

• Status: Completed
• Trial end date: 2017-07-30
• Target enrollment: 0
• Participant gender: All

Summary

Personalized therapy as prophylaxis in ischemic stroke patients is not yet an option. From patients with ischemic heart disease, we know that patients with in vitro high on treatment platelet reactivity (HTPR) have an increased risk of stent thrombosis following per-cutaneous coronary intervention. Other studies have shown association of CYP2C19 genotypes with different responses to the anti platelet drug Clopidogrel. We measure HTPR in ischemic stroke patients on increasing doses of clopidogrel and investigate the CYP2C19 genotype for each patient.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zealand University Hospital
• Treatments: Clopidogrel

Criteria

Inclusion Criteria:

• Ischemic stroke diagnosis

• treatment with clopidogrel 75 mg/day

Exclusion Criteria:

• increased risk of bleeding

• treatment with NOAC, vitamin K antagonist or other antiplatelet drug than clopidogrel

• unable to give informed consent